hematological-malignancies

Documents about hematological-malignancies

• The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies#287558ClinicalTrials.gov
• Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome#872623ClinicalTrials.gov
• Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies#913505ClinicalTrials.gov
• Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies#902104ClinicalTrials.gov
• GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies#810075ClinicalTrials.gov
• A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies#910368ClinicalTrials.gov
• Rationale and Methods of a Surveillance System for Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies: A Qualitative Participatory Action Research Approach in Middle-Income Countries-The Experience in Iran.#433871NCBI PubMed Central
• Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation#910024ClinicalTrials.gov
• Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation#363633ClinicalTrials.gov
• Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors#904256ClinicalTrials.gov
• A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.#896808ClinicalTrials.gov
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies#836103ClinicalTrials.gov
• Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment#844859ClinicalTrials.gov
• Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)#864645ClinicalTrials.gov
• A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies#1009147ClinicalTrials.gov
• Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation#840288ClinicalTrials.gov
• Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT#862229ClinicalTrials.gov
• Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation#841539ClinicalTrials.gov
• Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells#982057ClinicalTrials.gov
• Epidemiology of resistant bacterial infections in patients with hematological malignancies or undergoing hematopoietic cell transplantation in Europe: A systematic review by the European Conference on Infections in Leukemia (ECIL)#231805IRIS
• HLA-matched versus haploidentical donor transplantation with post-transplant cyclophosphamide: a study on behalf of the donor/source working group of the Japanese society for transplantation and cellular therapy#295526OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Dysregulation Of JAK-STAT Pathway In Hematological Malignancies And JAK Inhibitors For Clinical Application#19603OpenCitations
• Study Evaluating Venetoclax in Subjects With Hematological Malignancies#805982ClinicalTrials.gov
• B-Cell Hematologic Malignancy Vaccination Registry#842477ClinicalTrials.gov
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep#843050ClinicalTrials.gov
• Successful Use of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with Lisocabtagene Maraleucel in a Renal Transplant Recipient with Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)#219205ODU Digital Commons
• An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies#870811ClinicalTrials.gov
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies#869700ClinicalTrials.gov
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies#886273ClinicalTrials.gov
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant#184919ClinicalTrials.gov
• HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies#835361ClinicalTrials.gov
• HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies#837980ClinicalTrials.gov
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant#861290ClinicalTrials.gov
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies#992687ClinicalTrials.gov
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies#915563ClinicalTrials.gov